NASDAQ:NVAX - Novavax Stock Price, Forecast & News

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Shares of Novavax reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($0.98) by $0.24. The biopharmaceutical company earned $2.51 million during the quarter, compared to analysts' expectations of $4.40 million. During the same quarter last year, the firm posted ($2.40) EPS. View Novavax's Earnings History.

Novavax is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Novavax.

9 Wall Street analysts have issued 1-year price objectives for Novavax's shares. Their forecasts range from $7.00 to $27.50. On average, they anticipate Novavax's share price to reach $15.93 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price. View Analyst Price Targets for Novavax.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax.

News headlines about NVAX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novavax earned a news impact score of 1.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the company's share price in the immediate future. View News Stories for Novavax.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Trevena (TRVN), Gilead Sciences (GILD), Opko Health (OPK) and Ocular Therapeutix (OCUL).

Novavax's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.33%), Charles Schwab Investment Management Inc. (0.46%), Bank of New York Mellon Corp (0.40%), TSP Capital Management Group LLC (0.39%), Ladenburg Thalmann Financial Services Inc. (0.14%) and Virtu Financial LLC (0.13%). Company insiders that own Novavax stock include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View Institutional Ownership Trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Bank of America Corp DE, Virtu Financial LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Sargent Investment Group LLC and Sargent Investment Group LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino and Michael A Mcmanus Jr. View Insider Buying and Selling for Novavax.

NVAX stock was bought by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Ikarian Capital LLC, UBS Group AG, Raymond James & Associates, Ladenburg Thalmann Financial Services Inc., Charles Schwab Investment Management Inc., Barclays PLC and State Street Corp. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, John Trizzino, Rachel K King and Stanley C Erck. View Insider Buying and Selling for Novavax.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVAX stock can currently be purchased for approximately $9.47.

Novavax has a market capitalization of $304.02 million and generates $34.29 million in revenue each year. The biopharmaceutical company earns $-184,750,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. Novavax employs 373 workers across the globe.View Additional Information About Novavax.

The official website for Novavax is http://www.novavax.com/.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]